Core Viewpoint - Jimin Health (603222) has experienced significant stock price increases, with a maximum cumulative rise of over 70% from August 14 to September 4, 2025, including 9 trading days of limit-up [1][2]. Group 1: Stock Performance - Jimin Health's stock price closed at 11.52 CNY per share on September 4, 2025, after reaching a high of 12.67 CNY and a low of 7.24 CNY during the period [1][2]. - The stock recorded a total trading volume of 13.69 million shares, with a turnover amounting to 14.145 billion CNY and a turnover rate of 260.81% [2]. Group 2: Shareholder Actions - The controlling shareholder, Shuangge Group, plans to reduce its holdings by up to 15,752,718 shares, representing no more than 3% of the total share capital, due to its own funding needs [4]. - The reduction will occur through a combination of centralized bidding (up to 5,250,906 shares) and block trading (up to 10,501,812 shares) between September 29 and December 26, 2025 [4]. Group 3: Financial Performance - For the first half of 2025, Jimin Health reported total revenue of 366 million CNY, a year-on-year decline of 21.30% [5]. - The company incurred a net loss attributable to shareholders of 52.6959 million CNY, primarily due to reduced income from medical device sales and inventory write-downs [5]. - The net cash flow from operating activities was negative, attributed to decreased cash receipts from sales and increased cash outflows due to litigation-related fund freezes [5].

Group 1 - Jimin Health announced that its controlling shareholder, Shuangge Group, plans to reduce its stake by up to 15,752,718 shares, representing no more than 3% of the total share capital [2][5] - The reduction will occur through two methods: a maximum of 5,250,906 shares via centralized bidding and up to 10,501,812 shares through block trading [5] - The reduction period is set from September 29, 2025, to December 26, 2025, and is driven by Shuangge Group's need for funds [5][6] Group 2 - Jimin Health's stock price reached a closing price of 11.52 yuan per share on September 4, with a significant increase of over 70% in the last 16 trading days, including 9 trading days of price limits [3] - As of August 29, 2025, the total shares held by the controlling shareholder and its concerted parties amounted to 234 million shares, with 159 million shares pledged, representing 67.8% of their holdings and 30.19% of the total shares [5][6] Group 3 - In the first half of 2025, Jimin Health reported total revenue of 366 million yuan, a year-on-year decline of 21.3% [6] - The company experienced a net loss attributable to shareholders of 52.7 million yuan, primarily due to reduced income and profits from medical device sales, influenced by U.S. tariff policies and other factors [6] - The negative cash flow from operating activities was mainly due to decreased cash receipts from sales and increased cash payments related to operating activities [6]